Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Janet Sue Rader MD

Chairman, Professor

Institution: Medical College of Wisconsin
Department: Obstetrics and Gynecology
Division: Administration
Program: Obstetrics and Gynecology

Member of the Cancer Center


Publications

  • Polymorphisms in immune mediators associate with risk of cervical cancer. (Zhang Z, Fye S, Borecki IB, Rader JS) Gynecol Oncol 2014 Oct;135(1):69-73 PMID: 25127987 PMCID: PMC4198466
  • 3-T MRI-based adaptive brachytherapy for cervix cancer: treatment technique and initial clinical outcomes. (Kharofa J, Morrow N, Kelly T, Rownd J, Paulson E, Rader J, Uyar D, Bradley W, Erickson B) Brachytherapy 2014 Jul-Aug;13(4):319-25 PMID: 24837024
  • AKT inhibitors promote cell death in cervical cancer through disruption of mTOR signaling and glucose uptake. (Rashmi R, DeSelm C, Helms C, Bowcock A, Rogers BE, Rader JL, Grigsby PW, Schwarz JK) PLoS One 2014;9(4):e92948 PMID: 24705275 PMCID: PMC3976291
  • Hypermethylation of miR-203 in endometrial carcinomas. (Huang YW, Kuo CT, Chen JH, Goodfellow PJ, Huang TH, Rader JS, Uyar DS) Gynecol Oncol 2014 May;133(2):340-5 PMID: 24530564 PMCID: PMC4015135
  • Genomics of cervical cancer and the role of human papillomavirus pathobiology. (Uyar D, Rader J) Clin Chem 2014 Jan;60(1):144-6 PMID: 24046199
  • A statement on abortion by 100 professors of obstetrics: 40 years later. (One Hundred Professors of Obstetrics and Gynecology) Contraception 2013 Oct;88(4):568-76 PMID: 24034806
  • Genetic variations in EGFR and ERBB4 increase susceptibility to cervical cancer. (Ma D, Hovey RL, Zhang Z, Fye S, Huettner PC, Borecki IB, Rader JS) Gynecol Oncol 2013 Nov;131(2):445-50 PMID: 23927961 PMCID: PMC3831657
  • Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. (Zighelboim I, Wright JD, Gao F, Case AS, Massad LS, Mutch DG, Powell MA, Thaker PH, Eisenhauer EL, Cohn DE, Valea FA, Alvarez Secord A, Lippmann LT, Dehdashti F, Rader JS) Gynecol Oncol 2013 Jul;130(1):64-8 PMID: 23591400 PMCID: PMC3870479
  • A statement on abortion by 100 professors of obstetrics: 40 years later. (One Hundred Professors of Obstetrics and Gynecology) Am J Obstet Gynecol 2013 Sep;209(3):193-9 PMID: 23500455
  • Pathway index models for construction of patient-specific risk profiles. (Eng KH, Wang S, Bradley WH, Rader JS, Kendziorski C) Stat Med 2013 Apr 30;32(9):1524-35 PMID: 23074142 PMCID: PMC3593986
  • Post-radiation damage to the pelvic girdle in cervical cancer patients: Is intensity modulated radiation therapy safer than conventional radiation? (Ioffe Y, Hillen T, Zhou G, Schwarz J, Mutch D, Powell M, Rader J, Zighelboim I, Hagemann A, Thaker P) Gynecol Oncol 2012 Oct;127(1 Suppl):S10 PMID: 24989513
  • Pathway-specific analysis of gene expression data identifies the PI3K/Akt pathway as a novel therapeutic target in cervical cancer. (Schwarz JK, Payton JE, Rashmi R, Xiang T, Jia Y, Huettner P, Rogers BE, Yang Q, Watson M, Rader JS, Grigsby PW) Clin Cancer Res 2012 Mar 1;18(5):1464-71 PMID: 22235101 PMCID: PMC3627483
  • Integrated genomic analyses of ovarian carcinoma. (Cancer Genome Atlas Research Network) Nature 2011 Jun 30;474(7353):609-15 PMID: 21720365 PMCID: PMC3163504
  • Cost-benefit of laparoscopic versus medical ovarian suppression in premenopausal breast cancer. (Hagemann AR, Zighelboim I, Odibo AO, Rader JS, Mutch DG, Powell MA) Breast J 2011 Jan-Feb;17(1):103-5 PMID: 21155918
  • The effects of body mass index on complications and survival outcomes in patients with cervical carcinoma undergoing curative chemoradiation therapy. (Kizer NT, Thaker PH, Gao F, Zighelboim I, Powell MA, Rader JS, Mutch DG, Grigsby PW) Cancer 2011 Mar 1;117(5):948-56 PMID: 20945318 PMCID: PMC4080792
  • HLA-Cw group 1 ligands for KIR increase susceptibility to invasive cervical cancer. (Martin MP, Borecki IB, Zhang Z, Nguyen L, Ma D, Gao X, Qi Y, Carrington M, Rader JS) Immunogenetics 2010 Dec;62(11-12):761-5 PMID: 20857097 PMCID: PMC3043355
  • A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies. (Fracasso PM, Williams KJ, Chen RC, Picus J, Ma CX, Ellis MJ, Tan BR, Pluard TJ, Adkins DR, Naughton MJ, Rader JS, Arquette MA, Fleshman JW, Creekmore AN, Goodner SA, Wright LP, Guo Z, Ryan CE, Tao Y, Soares EM, Cai SR, Lin L, Dancey J, Rudek MA, McLeod HL, Piwnica-Worms H) Cancer Chemother Pharmacol 2011 Jun;67(6):1225-37 PMID: 20694727 PMCID: PMC3102212
  • Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis. (Kidd EA, Siegel BA, Dehdashti F, Rader JS, Mutch DG, Powell MA, Grigsby PW) J Clin Oncol 2010 Apr 20;28(12):2108-13 PMID: 20308664
  • TP53, MDM2, NQO1, and susceptibility to cervical cancer. (Hu X, Zhang Z, Ma D, Huettner PC, Massad LS, Nguyen L, Borecki I, Rader JS) Cancer Epidemiol Biomarkers Prev 2010 Mar;19(3):755-61 PMID: 20200430 PMCID: PMC2837516
  • A microRNA expression signature for cervical cancer prognosis. (Hu X, Schwarz JK, Lewis JS Jr, Huettner PC, Rader JS, Deasy JO, Grigsby PW, Wang X) Cancer Res 2010 Feb 15;70(4):1441-8 PMID: 20124485 PMCID: PMC2844247
  • "Surgical Apgar Score" predicts postoperative complications after cytoreduction for advanced ovarian cancer. (Zighelboim I, Kizer N, Taylor NP, Case AS, Gao F, Thaker PH, Rader JS, Massad LS, Mutch DG, Powell MA) Gynecol Oncol 2010 Mar;116(3):370-3 PMID: 20015540
  • 18F-fluorodeoxyglucose-positron emission tomography and pathologic tumor size in early-stage invasive cervical cancer. (Showalter TN, Miller TR, Huettner P, Rader J, Grigsby PW) Int J Gynecol Cancer 2009 Nov;19(8):1412-4 PMID: 20009899
  • Polymorphisms in MMP9 and SIPA1 are associated with increased risk of nodal metastases in early-stage cervical cancer. (Brooks R, Kizer N, Nguyen L, Jaishuen A, Wanat K, Nugent E, Grigsby P, Allsworth JE, Rader JS) Gynecol Oncol 2010 Mar;116(3):539-43 PMID: 19906411 PMCID: PMC2822070
  • Chemoradiation in locally advanced cervical carcinoma: an analysis of cisplatin dosing and other clinical prognostic factors. (Nugent EK, Case AS, Hoff JT, Zighelboim I, DeWitt LL, Trinkhaus K, Mutch DG, Thaker PH, Massad LS, Rader JS) Gynecol Oncol 2010 Mar;116(3):438-41 PMID: 19896180
  • Clinical outcomes of definitive intensity-modulated radiation therapy with fluorodeoxyglucose-positron emission tomography simulation in patients with locally advanced cervical cancer. (Kidd EA, Siegel BA, Dehdashti F, Rader JS, Mutic S, Mutch DG, Powell MA, Grigsby PW) Int J Radiat Oncol Biol Phys 2010 Jul 15;77(4):1085-91 PMID: 19880262
  • The value of perioperative imaging in patients with uterine sarcomas. (Nugent EK, Zighelboim I, Case AS, Gao F, Thaker PH, Rader JS, Mutch DG, Massad LS) Gynecol Oncol 2009 Oct;115(1):37-40 PMID: 19577795 PMCID: PMC4306556
  • The accuracy of colposcopic grading for detection of high-grade cervical intraepithelial neoplasia. (Massad LS, Jeronimo J, Katki HA, Schiffman M, National Institutes of Health/American Society for Colposcopy and Cervical Pathology Research Group) J Low Genit Tract Dis 2009 Jul;13(3):137-44 PMID: 19550210 PMCID: PMC2921444
  • ATR mutation in endometrioid endometrial cancer is associated with poor clinical outcomes. (Zighelboim I, Schmidt AP, Gao F, Thaker PH, Powell MA, Rader JS, Gibb RK, Mutch DG, Goodfellow PJ) J Clin Oncol 2009 Jul 1;27(19):3091-6 PMID: 19470935 PMCID: PMC2716934
  • Cervical cancer histology and tumor differentiation affect 18F-fluorodeoxyglucose uptake. (Kidd EA, Spencer CR, Huettner PC, Siegel BA, Dehdashti F, Rader JS, Grigsby PW) Cancer 2009 Aug 1;115(15):3548-54 PMID: 19472399
  • CD83 polymorphisms and cervical cancer risk. (Yu KJ, Rader JS, Borecki I, Zhang Z, Hildesheim A) Gynecol Oncol 2009 Aug;114(2):319-22 PMID: 19446866 PMCID: PMC2754395
  • Long-term assessment of bladder and bowel dysfunction after radical hysterectomy. (Brooks RA, Wright JD, Powell MA, Rader JS, Gao F, Mutch DG, Wall LL) Gynecol Oncol 2009 Jul;114(1):75-9 PMID: 19410279
  • Cardiac arrest during laparotomy with argon beam coagulation of metastatic ovarian cancer. (Kizer N, Zighelboim I, Rader JS) Int J Gynecol Cancer 2009 Feb;19(2):237-8 PMID: 19395999
  • Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6. (Wang X, Wang HK, McCoy JP, Banerjee NS, Rader JS, Broker TR, Meyers C, Chow LT, Zheng ZM) RNA 2009 Apr;15(4):637-47 PMID: 19258450 PMCID: PMC2661824
  • Sequential chemotherapy and irradiation in advanced stage endometrial cancer: A Gynecologic Oncology Group phase I trial of doxorubicin-cisplatin followed by whole abdomen irradiation. (Fowler JM, Brady WE, Grigsby PW, Cohn DE, Mannel RS, Rader JS) Gynecol Oncol 2009 Mar;112(3):553-7 PMID: 19135232
  • A unified sample preparation protocol for proteomic and genomic profiling of cervical swabs to identify biomarkers for cervical cancer screening. (Rader JS, Malone JP, Gross J, Gilmore P, Brooks RA, Nguyen L, Crimmins DL, Feng S, Wright JD, Taylor N, Zighelboim I, Funk MC, Huettner PC, Ladenson JH, Gius D, Townsend RR) Proteomics Clin Appl 2008 Dec;2(12):1658-69 PMID: 21136816 PMCID: PMC3042129
  • Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer. (Brooks RA, Rader JS, Dehdashti F, Mutch DG, Powell MA, Thaker PH, Siegel BA, Grigsby PW) Gynecol Oncol 2009 Jan;112(1):104-9 PMID: 18929403 PMCID: PMC4398307
  • Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer. (Herzog TJ, Powell MA, Rader JS, Gibb RK, Lippmann L, Coleman RL, Mutch DG) Gynecol Oncol 2008 Dec;111(3):467-73 PMID: 18834619
  • Effects of cancer treatment on ovarian function. (Stroud JS, Mutch D, Rader J, Powell M, Thaker PH, Grigsby PW) Fertil Steril 2009 Aug;92(2):417-27 PMID: 18774559
  • Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. (Wang X, Tang S, Le SY, Lu R, Rader JS, Meyers C, Zheng ZM) PLoS One 2008;3(7):e2557 PMID: 18596939 PMCID: PMC2438475
  • Differential display identifies overexpression of the USP36 gene, encoding a deubiquitinating enzyme, in ovarian cancer. (Li J, Olson LM, Zhang Z, Li L, Bidder M, Nguyen L, Pfeifer J, Rader JS) Int J Med Sci 2008;5(3):133-42 PMID: 18566677 PMCID: PMC2424181
  • Phase I study and preliminary pharmacology of the novel innate immune modulator rBBX-01 in gynecologic cancers. (Rader JS, Aylsworth CF, Juckett DA, Mutch DG, Powell MA, Lippmann L, Dimitrov NV) Clin Cancer Res 2008 May 15;14(10):3089-97 PMID: 18483376
  • Identification of novel methylation markers in cervical cancer using restriction landmark genomic scanning. (Wang SS, Smiraglia DJ, Wu YZ, Ghosh S, Rader JS, Cho KR, Bonfiglio TA, Nayar R, Plass C, Sherman ME) Cancer Res 2008 Apr 1;68(7):2489-97 PMID: 18381458
  • Prognostic factors associated with response in platinum retreatment of platinum-resistant ovarian cancer. (Nguyen TT, Wright JD, Powell MA, Gibb RK, Rader JS, Allsworth JE, Mutch DG) Int J Gynecol Cancer 2008 Nov-Dec;18(6):1194-9 PMID: 18217964
  • CD83 gene polymorphisms increase susceptibility to human invasive cervical cancer. (Zhang Z, Borecki I, Nguyen L, Ma D, Smith K, Huettner PC, Mutch DG, Herzog TJ, Gibb RK, Powell MA, Grigsby PW, Massad LS, Hernandez E, Judson PL, Swisher EM, Crowder S, Li J, Gerhard DS, Rader JS) Cancer Res 2007 Dec 1;67(23):11202-8 PMID: 18056445
  • Acute toxicity of postoperative IMRT and chemotherapy for endometrial cancer. (Tierney RM, Powell MA, Mutch DG, Gibb RK, Rader JS, Grigsby PW) Radiat Med 2007 Nov;25(9):439-45 PMID: 18026901
  • Bevacizumab therapy in patients with recurrent uterine neoplasms. (Wright JD, Powell MA, Rader JS, Mutch DG, Gibb RK) Anticancer Res 2007 Sep-Oct;27(5B):3525-8 PMID: 17972512
  • Evaluation of candidate methylation markers to detect cervical neoplasia. (Shivapurkar N, Sherman ME, Stastny V, Echebiri C, Rader JS, Nayar R, Bonfiglio TA, Gazdar AF, Wang SS) Gynecol Oncol 2007 Dec;107(3):549-53 PMID: 17894941 PMCID: PMC2718832
  • Effect of a T0 radical hysterectomy specimen on survival for early stage cervical cancer. (Wright JD, Grigsby PW, Rader JS, Mutch DG, Powell MA, Gao F, Gibb RK) Gynecol Oncol 2007 Nov;107(2):280-4 PMID: 17698175
  • Profiling microdissected epithelium and stroma to model genomic signatures for cervical carcinogenesis accommodating for covariates. (Gius D, Funk MC, Chuang EY, Feng S, Huettner PC, Nguyen L, Bradbury CM, Mishra M, Gao S, Buttin BM, Cohn DE, Powell MA, Horowitz NS, Whitcomb BP, Rader JS) Cancer Res 2007 Aug 1;67(15):7113-23 PMID: 17671178
  • Utility of parametrectomy for early stage cervical cancer treated with radical hysterectomy. (Wright JD, Grigsby PW, Brooks R, Powell MA, Gibb RK, Gao F, Rader JS, Mutch DG) Cancer 2007 Sep 15;110(6):1281-6 PMID: 17654664
  • A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer. (Wright JD, Secord AA, Numnum TM, Rocconi RP, Powell MA, Berchuck A, Alvarez RD, Gibb RK, Trinkaus K, Rader JS, Mutch DG) Int J Gynecol Cancer 2008 May-Jun;18(3):400-6 PMID: 17645510
  • Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type. (Zighelboim I, Goodfellow PJ, Gao F, Gibb RK, Powell MA, Rader JS, Mutch DG) J Clin Oncol 2007 May 20;25(15):2042-8 PMID: 17513808
  • External radiotherapy versus vaginal brachytherapy for patients with intermediate risk endometrial cancer. (Lin LL, Mutch DG, Rader JS, Powell MA, Grigsby PW) Gynecol Oncol 2007 Jul;106(1):215-20 PMID: 17482665
  • Comparison of high-dose-rate and low-dose-rate brachytherapy in the treatment of endometrial carcinoma. (Fayed A, Mutch DG, Rader JS, Gibb RK, Powell MA, Wright JD, Elnaqa I, Zoberi I, Grigsby PW) Int J Radiat Oncol Biol Phys 2007 Feb 1;67(2):480-4 PMID: 17141980
  • Outcomes in 24 selected patients with stage IVB cervical cancer and excellent performance status treated with radiotherapy and chemotherapy. (Zighelboim I, Taylor NP, Powell MA, Gibb RK, Rader JS, Mutch DG, Grigsby PW) Radiat Med 2006 Nov;24(9):625-30 PMID: 17111271
  • Body mass index: relationship to clinical, pathologic and features of microsatellite instability in endometrial cancer. (McCourt CK, Mutch DG, Gibb RK, Rader JS, Goodfellow PJ, Trinkaus K, Powell MA) Gynecol Oncol 2007 Mar;104(3):535-9 PMID: 17109938
  • Human papillomaviruses target the double-stranded RNA protein kinase pathway. (Hebner CM, Wilson R, Rader J, Bidder M, Laimins LA) J Gen Virol 2006 Nov;87(Pt 11):3183-93 PMID: 17030851
  • Cervical cancer prevention in the era of prophylactic vaccines: a preview for gynecologic oncologists. (Society of Gynecologic Oncologists Education Resource Panel Writing group, Collins Y, Einstein MH, Gostout BS, Herzog TJ, Massad LS, Rader JS, Wright J) Gynecol Oncol 2006 Sep;102(3):552-62 PMID: 16979432
  • Cervical tissue collection methods for RNA preservation: comparison of snap-frozen, ethanol-fixed, and RNAlater-fixation. (Wang SS, Sherman ME, Rader JS, Carreon J, Schiffman M, Baker CC) Diagn Mol Pathol 2006 Sep;15(3):144-8 PMID: 16932069
  • MLH3 mutation in endometrial cancer. (Taylor NP, Powell MA, Gibb RK, Rader JS, Huettner PC, Thibodeau SN, Mutch DG, Goodfellow PJ) Cancer Res 2006 Aug 1;66(15):7502-8 PMID: 16885347
  • Colposcopic accuracy of obstetrics and gynecology residents. (Baum ME, Rader JS, Gibb RK, McAlister RP, Powell MA, Mutch DG, Gao F, Wright JD) Gynecol Oncol 2006 Dec;103(3):966-70 PMID: 16875717
  • DNA mismatch repair and TP53 defects are early events in uterine carcinosarcoma tumorigenesis. (Taylor NP, Zighelboim I, Huettner PC, Powell MA, Gibb RK, Rader JS, Mutch DG, Edmonston TB, Goodfellow PJ) Mod Pathol 2006 Oct;19(10):1333-8 PMID: 16810312
  • Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer. (Herzog TJ, Powell MA, Rader JS, Gibb R, Mutch DG) Gynecol Oncol 2006 Nov;103(2):637-41 PMID: 16781766
  • Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis. (Wright JD, Hagemann A, Rader JS, Viviano D, Gibb RK, Norris L, Mutch DG, Powell MA) Cancer 2006 Jul 1;107(1):83-9 PMID: 16736514
  • Gene expression patterns in advanced human cervical cancer. (Grigsby PW, Watson M, Powell MA, Zhang Z, Rader JS) Int J Gynecol Cancer 2006 Mar-Apr;16(2):562-7 PMID: 16681726
  • CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan. (Gossner G, Coleman RL, Mutch DG, Horowitz NS, Rader JS, Gibb RK, Powell MA, Herzog TJ) Gynecol Oncol 2006 Oct;103(1):212-8 PMID: 16677696
  • Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. (Wright JD, Viviano D, Powell MA, Gibb RK, Mutch DG, Grigsby PW, Rader JS) Gynecol Oncol 2006 Nov;103(2):489-93 PMID: 16647106
  • Identification of chromosomal alterations important in the development of cervical intraepithelial neoplasia and invasive carcinoma using alignment of DNA microarray data. (Fitzpatrick MA, Funk MC, Gius D, Huettner PC, Zhang Z, Bidder M, Ma D, Powell MA, Rader JS) Gynecol Oncol 2006 Nov;103(2):458-62 PMID: 16647105
  • Aberrant promoter methylation and silencing of the POU2F3 gene in cervical cancer. (Zhang Z, Huettner PC, Nguyen L, Bidder M, Funk MC, Li J, Rader JS) Oncogene 2006 Aug 31;25(39):5436-45 PMID: 16607278
  • Human papillomavirus triage for young women with atypical squamous cells of undetermined significance. (Wright JD, Rader JS, Davila R, Powell MA, Mutch DG, Gao F, Gibb RK) Obstet Gynecol 2006 Apr;107(4):822-9 PMID: 16582118
  • Long-term outcome of women who undergo panniculectomy at the time of gynecologic surgery. (Wright JD, Rosenbush EJ, Powell MA, Rader JS, Mutch DG, Gao F, Gibb RK) Gynecol Oncol 2006 Jul;102(1):86-91 PMID: 16406112
  • Preoperative lymph node staging of early-stage cervical carcinoma by [18F]-fluoro-2-deoxy-D-glucose-positron emission tomography. (Wright JD, Dehdashti F, Herzog TJ, Mutch DG, Huettner PC, Rader JS, Gibb RK, Powell MA, Gao F, Siegel BA, Grigsby PW) Cancer 2005 Dec 1;104(11):2484-91 PMID: 16270319
  • Relationship of ovarian neoplasms and body mass index. (Wright JD, Powell MA, Mutch DG, Rader JS, Gibb RK, Gao F, Herzog TJ) J Reprod Med 2005 Aug;50(8):595-602 PMID: 16220765
  • Resource utilization for ovarian cancer patients at the end of life: how much is too much? (Lewin SN, Buttin BM, Powell MA, Gibb RK, Rader JS, Mutch DG, Herzog TJ) Gynecol Oncol 2005 Nov;99(2):261-6 PMID: 16140364
  • Cervical sarcomas: an analysis of incidence and outcome. (Wright JD, Rosenblum K, Huettner PC, Mutch DG, Rader JS, Powell MA, Gibb RK) Gynecol Oncol 2005 Nov;99(2):348-51 PMID: 16051326
  • Cervical dysplasia in adolescents. (Wright JD, Davila RM, Pinto KR, Merritt DF, Gibb RK, Rader JS, Mutch DG, Gao F, Powell MA) Obstet Gynecol 2005 Jul;106(1):115-20 PMID: 15994625
  • FDG-PET evaluation of vaginal carcinoma. (Lamoreaux WT, Grigsby PW, Dehdashti F, Zoberi I, Powell MA, Gibb RK, Rader JS, Mutch DG, Siegel BA) Int J Radiat Oncol Biol Phys 2005 Jul 1;62(3):733-7 PMID: 15936553
  • Human papillomavirus type and tobacco use as predictors of survival in early stage cervical carcinoma. (Wright JD, Li J, Gerhard DS, Zhang Z, Huettner PC, Powell MA, Gibb RK, Herzog TJ, Mutch DG, Trinkaus KM, Rader JS) Gynecol Oncol 2005 Jul;98(1):84-91 PMID: 15894364
  • Fine mapping and evaluation of candidate genes for cervical cancer on 11q23. (Zhang Z, Gerhard DS, Nguyen L, Li J, Traugott A, Huettner PC, Rader JS) Genes Chromosomes Cancer 2005 May;43(1):95-103 PMID: 15672406
  • Cervix carcinoma, concurrent chemoradiotherapy, and salvage of isolated paraaortic lymph node recurrence. (Singh AK, Grigsby PW, Rader JS, Mutch DG, Powell MA) Int J Radiat Oncol Biol Phys 2005 Feb 1;61(2):450-5 PMID: 15667966
  • Lack of benefit of concurrent chemotherapy in patients with cervical cancer and negative lymph nodes by FDG-PET. (Grigsby PW, Mutch DG, Rader J, Herzog TJ, Zoberi I, Siegel BA, Dehdashti F) Int J Radiat Oncol Biol Phys 2005 Feb 1;61(2):444-9 PMID: 15667965
  • IGSF4 promoter methylation and expression silencing in human cervical cancer. (Li J, Zhang Z, Bidder M, Funk MC, Nguyen L, Goodfellow PJ, Rader JS) Gynecol Oncol 2005 Jan;96(1):150-8 PMID: 15589594
  • Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer. (Horowitz NS, Dehdashti F, Herzog TJ, Rader JS, Powell MA, Gibb RK, Grigsby PW, Siegel BA, Mutch DG) Gynecol Oncol 2004 Dec;95(3):546-51 PMID: 15581961
  • Cervical carcinoma in the elderly: an analysis of patterns of care and outcome. (Wright JD, Gibb RK, Geevarghese S, Powell MA, Herzog TJ, Mutch DG, Grigsby PW, Gao F, Trinkaus KM, Rader JS) Cancer 2005 Jan 1;103(1):85-91 PMID: 15540239
  • Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies. (Fracasso PM, Goldstein LJ, de Alwis DP, Rader JS, Arquette MA, Goodner SA, Wright LP, Fears CL, Gazak RJ, Andre VA, Burgess MF, Slapak CA, Schellens JH) Clin Cancer Res 2004 Nov 1;10(21):7220-8 PMID: 15534095
  • A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference? (Rutledge TL, Kamelle SA, Tillmanns TD, Gould NS, Wright JD, Cohn DE, Herzog TJ, Rader JS, Gold MA, Johnson GA, Walker JL, Mannel RS, McMeekin DS) Gynecol Oncol 2004 Oct;95(1):70-6 PMID: 15385112
  • Expression and localization of GRP75 in human epithelial tumors and normal tissues. (Srokowski T, Pfeifer JD, Li J, Olson LM, Rader JS) Appl Immunohistochem Mol Morphol 2004 Jun;12(2):132-8 PMID: 15354738
  • Panniculectomy: improving lymph node yield in morbidly obese patients with endometrial neoplasms. (Wright JD, Powell MA, Herzog TJ, Mutch DG, Rader JS, Gao F, Gibb RK) Gynecol Oncol 2004 Aug;94(2):436-41 PMID: 15297185
  • Surgical-pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply? (Kamelle SA, Rutledge TL, Tillmanns TD, Gould NS, Cohn DE, Wright J, Herzog TJ, Rader JS, Gold MA, Johnson GA, Walker JL, Mannel RS, McMeekin DS) Gynecol Oncol 2004 Aug;94(2):249-55 PMID: 15297159
  • Lymph node control in cervical cancer. (Grigsby PW, Singh AK, Siegel BA, Dehdashti F, Rader J, Zoberi I) Int J Radiat Oncol Biol Phys 2004 Jul 1;59(3):706-12 PMID: 15183474
  • Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. (Grigsby PW, Siegel BA, Dehdashti F, Rader J, Zoberi I) J Clin Oncol 2004 Jun 1;22(11):2167-71 PMID: 15169804
  • Penetrance and expressivity of MSH6 germline mutations in seven kindreds not ascertained by family history. (Buttin BM, Powell MA, Mutch DG, Babb SA, Huettner PC, Edmonston TB, Herzog TJ, Rader JS, Gibb RK, Whelan AJ, Goodfellow PJ) Am J Hum Genet 2004 Jun;74(6):1262-9 PMID: 15098177 PMCID: PMC1182090
  • Double cervix with bilateral and synchronous HSIL associated with different high-risk HPV types. A case report. (Pinto KR, Lu DW, Rader JS, Dávila RM) Acta Cytol 2004 Mar-Apr;48(2):273-7 PMID: 15085767
  • Synchronous ovarian metastases at the time of laparotomy for colon cancer. (Wright JD, Powell MA, Mutch DG, Rader JS, Gibb RK, Huettner PC, Herzog TJ) Gynecol Oncol 2004 Mar;92(3):851-5 PMID: 14984952
  • Increased risk for hereditary nonpolyposis colorectal cancer-associated synchronous and metachronous malignancies in patients with microsatellite instability-positive endometrial carcinoma lacking MLH1 promoter methylation. (Buttin BM, Powell MA, Mutch DG, Rader JS, Herzog TJ, Gibb RK, Huettner P, Edmonston TB, Goodfellow PJ) Clin Cancer Res 2004 Jan 15;10(2):481-90 PMID: 14760069
  • Denaturing high-performance liquid chromatography for detecting and typing genital human papillomavirus. (Li J, Gerhard DS, Zhang Z, Huettner PC, Wright J, Nguyen L, Lu D, Rader JS) J Clin Microbiol 2003 Dec;41(12):5563-71 PMID: 14662941 PMCID: PMC309016
  • A phase II study to determine the efficacy and tolerability of intravenous ZD9331 in heavily pretreated patients with ovarian cancer. (Rader JS, Clarke-Pearson D, Moore M, Carson L, Holloway R, Kao MS, Wiznitzer I, Douglass EC) Gynecol Oncol 2003 Nov;91(2):318-25 PMID: 14599861
  • A randomized phase II evaluation of bryostatin-1 (NSC #339555) in persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study. (Armstrong DK, Blessing JA, Rader J, Sorosky JI, Gynecologic Oncology Group Study) Invest New Drugs 2003 Nov;21(4):453-7 PMID: 14586213
  • Acute abdominal pain with a calcified pelvic mass. (Wright JD, Powell MA, Rader JS, Pfeifer JD, Huettner PC, Merritt DF) J Pediatr Adolesc Gynecol 2003 Aug;16(4):237-41 PMID: 14550387
  • Liquid-based cytology for the postirradiation surveillance of women with gynecologic malignancies. (Wright JD, Herzog TJ, Mutch DG, Gibb RK, Rader JS, Davila RM, Cohn DE) Gynecol Oncol 2003 Oct;91(1):134-8 PMID: 14529673
  • A relationship between methylenetetrahydrofolate reductase variants and the development of invasive cervical cancer. (Gerhard DS, Nguyen LT, Zhang ZY, Borecki IB, Coleman BI, Rader JS) Gynecol Oncol 2003 Sep;90(3):560-5 PMID: 13678724
  • Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies. (Fracasso PM, Rodriguez LC, Herzog TJ, Fears CL, Goodner SA, Govindan R, Picus J, Rader JS, Tan BR, Arquette MA) Cancer 2003 Aug 1;98(3):610-7 PMID: 12879480
  • Frequent HOXA11 and THBS2 promoter methylation, and a methylator phenotype in endometrial adenocarcinoma. (Whitcomb BP, Mutch DG, Herzog TJ, Rader JS, Gibb RK, Goodfellow PJ) Clin Cancer Res 2003 Jun;9(6):2277-87 PMID: 12796396
  • Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. (Goodfellow PJ, Buttin BM, Herzog TJ, Rader JS, Gibb RK, Swisher E, Look K, Walls KC, Fan MY, Mutch DG) Proc Natl Acad Sci U S A 2003 May 13;100(10):5908-13 PMID: 12732731 PMCID: PMC156300
  • Primary peritoneal carcinoma presenting as adenocarcinoma on a Pap smear. A case report. (Wright JD, Horowitz NS, Rader JS) J Reprod Med 2002 Nov;47(11):933-5 PMID: 12497684
  • Phase I study of rubitecan and gemcitabine in patients with advanced malignancies. (Fracasso PM, Rader JS, Govindan R, Herzog TJ, Arquette MA, Denes A, Mutch DG, Picus J, Tan BR, Fears CL, Goodner SA, Sun SL) Ann Oncol 2002 Nov;13(11):1819-25 PMID: 12419757
  • MSI in endometrial carcinoma: absence of MLH1 promoter methylation is associated with increased familial risk for cancers. (Whelan AJ, Babb S, Mutch DG, Rader J, Herzog TJ, Todd C, Ivanovich JL, Goodfellow PJ) Int J Cancer 2002 Jun 10;99(5):697-704 PMID: 12115503
  • Ribosomal DNA methylation in patients with endometrial carcinoma: an independent prognostic marker. (Powell MA, Mutch DG, Rader JS, Herzog TJ, Huang TH, Goodfellow PJ) Cancer 2002 Jun 1;94(11):2941-52 PMID: 12115383
  • The significance of pneumatosis intestinalis or bowel perforation in patients with gynecologic malignancies. (Horowitz NS, Cohn DE, Herzog TJ, Mutch DG, Rader JS, Bhalla S, Gibb RK) Gynecol Oncol 2002 Jul;86(1):79-84 PMID: 12079304
  • Microsatellite instability, MLH1 promoter methylation, and loss of mismatch repair in endometrial cancer and concomitant atypical hyperplasia. (Horowitz N, Pinto K, Mutch DG, Herzog TJ, Rader JS, Gibb R, Bocker-Edmonston T, Goodfellow PJ) Gynecol Oncol 2002 Jul;86(1):62-8 PMID: 12079302
  • Evaluation of the family history collection process and the accuracy of cancer reporting among a series of women with endometrial cancer. (Ivanovich J, Babb S, Goodfellow P, Mutch D, Herzog T, Rader J, Whelan A) Clin Cancer Res 2002 Jun;8(6):1849-56 PMID: 12060627
  • Mutation screening analysis of the retinoblastoma related gene RB2/p130 in sporadic ovarian cancer and head and neck squamous cell cancer. (Alvi AJ, Hogg R, Rader JS, Kuo MJ, Maher ER, Latif F) Mol Pathol 2002 Jun;55(3):153-5 PMID: 12032225 PMCID: PMC1187167
  • Utility and cost-effectiveness of preoperative autologous blood donation in gynecologic and gynecologic oncology patients. (Horowitz NS, Gibb RK, Menegakis NE, Mutch DG, Rader JS, Herzog TJ) Obstet Gynecol 2002 May;99(5 Pt 1):771-6 PMID: 11978286
  • Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulvar cancer. (Cohn DE, Dehdashti F, Gibb RK, Mutch DG, Rader JS, Siegel BA, Herzog TJ) Gynecol Oncol 2002 Apr;85(1):179-84 PMID: 11925141
  • Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study. (Bloss JD, Blessing JA, Behrens BC, Mannel RS, Rader JS, Sood AK, Markman M, Benda J) J Clin Oncol 2002 Apr 1;20(7):1832-7 PMID: 11919241
  • Use of complementary and alternative medicine among women with gynecologic cancers. (Swisher EM, Cohn DE, Goff BA, Parham J, Herzog TJ, Rader JS, Mutch DG) Gynecol Oncol 2002 Mar;84(3):363-7 PMID: 11855870
  • Phase II trial of pyrazoloacridine in patients with persistent or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. (Plaxe SC, Blessing JA, Husseinzadeh N, Webster KD, Rader JS, Dunton CJ) Gynecol Oncol 2002 Feb;84(2):241-4 PMID: 11812081
  • Epithelial ovarian tumors of low malignant potential: the role of microinvasion. (Buttin BM, Herzog TJ, Powell MA, Rader JS, Mutch DG) Obstet Gynecol 2002 Jan;99(1):11-7 PMID: 11777503
  • Role of the ultrasonic surgical aspirator in gynecology. (Horowitz NS, Rader JS) Obstet Gynecol Clin North Am 2001 Dec;28(4):775-90 PMID: 11766151
  • Genotypic and phenotypic progression in endometrial tumorigenesis: determining when defects in DNA mismatch repair and KRAS2 occur. (Cohn DE, Mutch DG, Herzog TJ, Rader JS, Dintzis SM, Gersell DJ, Todd CR, Goodfellow PJ) Genes Chromosomes Cancer 2001 Dec;32(4):295-301 PMID: 11746970
  • Factors predicting subcutaneous implanted central venous port function: the relationship between catheter tip location and port failure in patients with gynecologic malignancies. (Cohn DE, Mutch DG, Rader JS, Farrell M, Awantang R, Herzog TJ) Gynecol Oncol 2001 Dec;83(3):533-6 PMID: 11733967
  • Microsatellite instability and mutational analysis of transforming growth factor beta receptor type II gene (TGFBR2) in sporadic ovarian cancer. (Alvi AJ, Rader JS, Broggini M, Latif F, Maher ER) Mol Pathol 2001 Aug;54(4):240-3 PMID: 11477138 PMCID: PMC1187074
  • Loss of heterozygosity at 11q23.3 in vasculoinvasive and metastatic squamous cell carcinoma of the cervix. (O'sullivan MJ, Rader JS, Gerhard DS, Li Y, Trinkaus KM, Gersell DJ, Huettner PC) Hum Pathol 2001 May;32(5):475-8 PMID: 11381364
  • Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. (Agathanggelou A, Honorio S, Macartney DP, Martinez A, Dallol A, Rader J, Fullwood P, Chauhan A, Walker R, Shaw JA, Hosoe S, Lerman MI, Minna JD, Maher ER, Latif F) Oncogene 2001 Mar 22;20(12):1509-18 PMID: 11313894
  • Prophylactic oophorectomy and ovarian cancer surveillance. Patient perceptions and satisfaction. (Swisher EM, Babb S, Whelan A, Mutch DG, Rader JS) J Reprod Med 2001 Feb;46(2):87-94 PMID: 11255821
  • Cyclooxygenase-2 is overexpressed in human cervical cancer. (Kulkarni S, Rader JS, Zhang F, Liapis H, Koki AT, Masferrer JL, Subbaramaiah K, Dannenberg AJ) Clin Cancer Res 2001 Feb;7(2):429-34 PMID: 11234900
  • No evidence for BCL10 mutation in endometrial cancers with microsatellite instability. (Cohn D, Mutch D, Elbendary A, Rader J, Herzog T, Goodfellow P) Hum Mutat 2001 Feb;17(2):117-21 PMID: 11180594
  • Radiation therapy for carcinoma of the cervix with biopsy-proven positive para-aortic lymph nodes. (Grigsby PW, Perez CA, Chao KS, Herzog T, Mutch DG, Rader J) Int J Radiat Oncol Biol Phys 2001 Mar 1;49(3):733-8 PMID: 11172956
  • Clinical significance of microsatellite instability in endometrial carcinoma. (Basil JB, Goodfellow PJ, Rader JS, Mutch DG, Herzog TJ) Cancer 2000 Oct 15;89(8):1758-64 PMID: 11042571
  • Radical hysterectomy for cervical cancer in obese women. (Cohn DE, Swisher EM, Herzog TJ, Rader JS, Mutch DG) Obstet Gynecol 2000 Nov;96(5 Pt 1):727-31 PMID: 11042308
  • Absence of PTEN repeat tract mutation in endometrial cancers with microsatellite instability. (Cohn DE, Basil JB, Venegoni AR, Mutch DG, Rader JS, Herzog TJ, Gersell DJ, Goodfellow PJ) Gynecol Oncol 2000 Oct;79(1):101-6 PMID: 11006040
  • Management of women at risk for malignancy. (Basil JB, Rader JS) Curr Opin Oncol 2000 Sep;12(5):508-13 PMID: 10975560
  • Atypical clustering of gynecologic malignancies: A family study including molecular analysis of candidate genes. (Cohn DE, Babb S, Whelan AJ, Mutch DG, Herzog TJ, Rader JS, Elbendary A, Goodfellow PJ) Gynecol Oncol 2000 Apr;77(1):18-25 PMID: 10739686
  • Cervical cancer suppressor gene is within 1 cM on 6p23. (Rader JS, Li Y, Huettner PC, Xu Z, Gerhard DS) Genes Chromosomes Cancer 2000 Apr;27(4):373-9 PMID: 10719367
  • Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: a Phase II study of the gynecologic oncology group. (Schilder RJ, Blessing JA, Morgan M, Mangan CE, Rader JS) Gynecol Oncol 2000 Feb;76(2):204-7 PMID: 10637071
  • Association between DQB1 and cervical cancer in patients with human papillomavirus and family controls. (Neuman RJ, Huettner PC, Li L, Mardis ER, Duffy BF, Wilson RK, Rader JS) Obstet Gynecol 2000 Jan;95(1):134-40 PMID: 10636516
  • Lack of effect of tumor size on the prognosis of carcinoma of the uterine cervix Stage IB and IIA treated with preoperative irradiation and surgery. (Grigsby PW, Perez CA, Chao KS, Elbendary A, Herzog TJ, Rader JS, Mutch DG) Int J Radiat Oncol Biol Phys 1999 Oct 1;45(3):645-51 PMID: 10524418
  • Detailed genetic and physical mapping of tumor suppressor loci on chromosome 3p in ovarian cancer. (Fullwood P, Marchini S, Rader JS, Martinez A, Macartney D, Broggini M, Morelli C, Barbanti-Brodano G, Maher ER, Latif F) Cancer Res 1999 Sep 15;59(18):4662-7 PMID: 10493522
  • Mutational analysis of the PMS2 gene in sporadic endometrial cancers with microsatellite instability. (Basil JB, Swisher EM, Herzog TJ, Rader JS, Elbendary A, Mutch DG, Goodfellow PJ) Gynecol Oncol 1999 Sep;74(3):395-9 PMID: 10479499
  • Differences in patterns of TP53 and KRAS2 mutations in a large series of endometrial carcinomas with or without microsatellite instability. (Swisher EM, Peiffer-Schneider S, Mutch DG, Herzog TJ, Rader JS, Elbendary A, Goodfellow PJ) Cancer 1999 Jan 1;85(1):119-26 PMID: 9921983
  • Cancer among first-degree relatives of probands with invasive and borderline ovarian cancer. (Rader JS, Neuman RJ, Brady J, Babb S, Temple S, Kost E, Mutch DG, Herzog TJ) Obstet Gynecol 1998 Oct;92(4 Pt 1):589-95 PMID: 9764634
  • Mapping an endometrial cancer tumor suppressor gene at 10q25 and development of a bacterial clone contig for the consensus deletion interval. (Peiffer-Schneider S, Noonan FC, Mutch DG, Simpkins SB, Herzog T, Rader J, Elbendary A, Gersell DJ, Call K, Goodfellow PJ) Genomics 1998 Aug 15;52(1):9-16 PMID: 9740666
  • Analysis of MSH3 in endometrial cancers with defective DNA mismatch repair. (Swisher EM, Mutch DG, Herzog TJ, Rader JS, Kowalski LD, Elbendary A, Goodfellow PJ) J Soc Gynecol Investig 1998 Jul-Aug;5(4):210-6 PMID: 9699180
  • Cervical intraepithelial neoplasia III shows frequent allelic loss in 3p and 6p. (Rader JS, Gerhard DS, O'Sullivan MJ, Li Y, Li L, Liapis H, Huettner PC) Genes Chromosomes Cancer 1998 May;22(1):57-65 PMID: 9591635
  • Loss of heterozygosity in clinical stage IB cervical carcinoma: relationship with clinical and histopathologic features. (Huettner PC, Gerhard DS, Li L, Gersell DJ, Dunnigan K, Kamarasova T, Rader JS) Hum Pathol 1998 Apr;29(4):364-70 PMID: 9563786
  • Topotecan in platinum- and paclitaxel-resistant ovarian cancer. (Swisher EM, Mutch DG, Rader JS, Elbendary A, Herzog TJ) Gynecol Oncol 1997 Sep;66(3):480-6 PMID: 9299264
  • Expression of alpha(v)beta3 integrin is less frequent in ovarian epithelial tumors of low malignant potential in contrast to ovarian carcinomas. (Liapis H, Adler LM, Wick MR, Rader JS) Hum Pathol 1997 Apr;28(4):443-9 PMID: 9104944
  • Mutational analysis of MLH1 and MSH2 in 25 prospectively-acquired RER+ endometrial cancers. (Kowalski LD, Mutch DG, Herzog TJ, Rader JS, Goodfellow PJ) Genes Chromosomes Cancer 1997 Mar;18(3):219-27 PMID: 9071575
  • Allelotyping of all chromosomal arms in invasive cervical cancer. (Rader JS, Kamarasova T, Huettner PC, Li L, Li Y, Gerhard DS) Oncogene 1996 Dec 19;13(12):2737-41 PMID: 9000149
  • Potential of cervical electrosurgical excision procedure for diagnosis and treatment of cervical intraepithelial neoplasia. (Herzog TJ, Williams S, Adler LM, Rader JS, Kubiniec RT, Camel HM, Mutch DG) Gynecol Oncol 1995 Jun;57(3):286-93 PMID: 7774831
  • Ovarian artery pseudoaneurysm: diagnosis by Doppler sonography and treatment with transcatheter embolization. (Ball RH, Picus D, Goyal RK, Wilson DB, Rader JS) J Ultrasound Med 1995 Mar;14(3):250-2 PMID: 7760472
  • Analysis of exposure times and dose escalation of paclitaxel in ovarian cancer cell lines. (Adler LM, Herzog TJ, Williams S, Rader JS, Mutch DG) Cancer 1994 Oct 1;74(7):1891-8 PMID: 7915965
  • In situ localization of parathyroid hormone-like protein and mRNA in intraepithelial neoplasia and invasive carcinoma of the uterine cervix. (Liapis H, Crouch EC, Roby J, Rader JS) Hum Pathol 1993 Oct;24(10):1058-66 PMID: 8406415
  • A comparison of wound healing after epithelial resection by ultrasonic surgical aspiration and ablation by the carbon dioxide laser. (Rader JS, Rest EB, Farmer ER, Rosenshein NB) Gynecol Oncol 1992 Sep;46(3):351-6 PMID: 1526514
  • Therapeutic advances in ovarian cancer. (Rader JS) Curr Opin Obstet Gynecol 1992 Feb;4(1):120-7 PMID: 1543823
  • HPV-16 viral transcripts in vulvar neoplasia: preliminary studies. (Park JS, Rader JS, Wu TC, Laimins LA, Currie JL, Kurman RJ, Shah KV) Gynecol Oncol 1991 Sep;42(3):250-5 PMID: 1659554
  • Retroperitoneal lymphatic involvement with epithelial ovarian tumors of low malignant potential. (Leake JF, Rader JS, Woodruff JD, Rosenshein NB) Gynecol Oncol 1991 Aug;42(2):124-30 PMID: 1894170
  • Detection of transcripts of human papillomaviruses 16 and 18 in cancer-derived cell lines and cervical biopsies by enzyme immunoassay for DNA-RNA hybrids following solution hybridization. (Coutlée F, Shah KV, Rader JS, Currie JL, Viscidi RP) J Clin Microbiol 1991 May;29(5):968-74 PMID: 1647410 PMCID: PMC269917
  • Ultrasonic surgical aspiration in the treatment of vulvar disease. (Rader JS, Leake JF, Dillon MB, Rosenshein NB) Obstet Gynecol 1991 Apr;77(4):573-6 PMID: 2002980
  • Atypical squamous cells. A case-series study of the association between papanicolaou smear results and human papillomavirus DNA genotype. (Rader JS, Rosenzweig BA, Spirtas R, Padleckas R, Javaheri G, Gerardo L, Laimins LA) J Reprod Med 1991 Apr;36(4):291-7 PMID: 1649307
  • Ileal hemorrhage caused by a parasitic uterine leiomyoma. (Rader JS, Binette SP, Brandt TD, Sreekanth S, Chhablani A) Obstet Gynecol 1990 Sep;76(3 Pt 2):531-4 PMID: 2381642
  • Radiation therapy in the treatment of cervical cancer: the University of Chicago/Michael Reese Hospital experience. (Rader JS, Haraf DJ, Halpern HJ, Rotmensch J, Spelbring DR, Sutton H, Javaheri G, Weichselbaum RR) J Surg Oncol 1990 Jul;44(3):157-65 PMID: 2370799
  • In vitro differentiation of epithelial cells from cervical neoplasias resembles in vivo lesions. (Rader JS, Golub TR, Hudson JB, Patel D, Bedell MA, Laimins LA) Oncogene 1990 Apr;5(4):571-6 PMID: 1691480
  • The mons pubis: an excellent graft donor site in gynecologic surgery. (Dudzinski MR, Rader JS) Am J Obstet Gynecol 1990 Mar;162(3):722-5 PMID: 2316577
  • Last update: 06/28/2015